We are live on ! Find out more
BIOTW

Biotech Acquisition Company Warrant
BIOTW

Delisted

BIOTW was delisted on the 2nd of February, 2023.

Back to rankings

52 hedge funds and large institutions have $5.06M invested in Biotech Acquisition Company Warrant in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less funds holding

Funds holding: 56 → 52 (-4)

18% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 11

40% less capital invested

Capital invested by funds: $8.44M → $5.06M (-$3.38M)

44% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 9

Holders
52
Holders Change
-4
Holders Change %
-7.14%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
9
Reduced
11
Closed
9
Calls
$5.74M
Puts
–
Net Calls
+$5.74M
Net Calls Change
-$37K

Top Buyers

Rank Fund Capital Flow
1
HIM
HGC Investment Management
Ontario, Canada
+$212K
2
KSCM
Kamunting Street Capital Management
Florida
+$50.7K
3
QGA
Q Global Advisors
Texas
+$43.2K
4
SCM
Shaolin Capital Management
Florida
+$14.9K
5
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
+$7.97K

Top Sellers

Rank Fund Capital Flow
1
RA
Ramius Advisors
New York
-$299K
2
Blackstone Inc
Blackstone Inc
New York
-$165K
3
FTCM
Fir Tree Capital Management
New York
-$82K
4
AGM
Alpine Global Management
New York
-$67K
5
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
-$66K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
Radcliffe Capital Management
Pennsylvania
$2M – – –
LP
2
LMR Partners
United Kingdom
$493K – – –
SCM
3
Segantii Capital Management
Hong Kong
$493K – – –
BFM
4
Boothbay Fund Management
New York
$308K +$4.89K +15,323 +96%
HIM
5
HGC Investment Management
Ontario, Canada
$292K +$212K +664,832 +121%
AC
6
Aristeia Capital
Connecticut
$251K -$128 -400 -0%
Citadel Advisors
7
Citadel Advisors
Florida
$117K +$128 +400 +0.1%
CCP
8
Corbin Capital Partners
New York
$111K – – –
KCM
9
Kingstown Capital Management
New York
$72K – – –
QGA
10
Q Global Advisors
Texas
$72K +$43.2K +135,332 +82%
SRCM
11
Sage Rock Capital Management
New York
$69K – – –
ACM
12
Atalaya Capital Management
New York
$67K – – –
LA
13
Linden Advisors
New York
$57K -$30K -93,957 -28%
MF
14
Magnetar Financial
Illinois
$49K -$3.76K -11,796 -5%
PAMP
15
Polar Asset Management Partners
Ontario, Canada
$47K – – –
PC
16
Periscope Capital
Ontario, Canada
$40K -$1.53K -4,800 -3%
KSCM
17
Kamunting Street Capital Management
Florida
$38K +$50.7K +158,962 New
TI
18
Telemetry Investments
New York
$36K +$4.78K +15,000 +11%
SC
19
Sculptor Capital
New York
$35K – – –
MI
20
MMCAP International
Cayman Islands
$34K – – –
TCM
21
Tenor Capital Management
New York
$34K – – –
DKCM
22
Davidson Kempner Capital Management
New York
$31K – – –
RCM
23
Rivernorth Capital Management
Florida
$27K -$530 -1,662 -1%
AC
24
Antara Capital
New York
$26K – – –
ACA
25
Arena Capital Advisors
California
$24K – – –
1
2 3

BIOTW Hedge Fund Activity: Q1 2022 in Review

52 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q1 2022, worth a combined $5.06M — down 40% from $8.44M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of BIOTW and 5 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 9 added.

The largest buyer was HGC Investment Management, adding an estimated $212K. The largest seller was Ramius Advisors, exiting entirely with an estimated $299K sold.

  • 52 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q1 2022, down from 56 in Q4 2021.
  • Funds reported $5.06M of Biotech Acquisition Company Warrant stock for Q1 2022, down 40% quarter-over-quarter.
  • 5 funds opened new Biotech Acquisition Company Warrant positions in Q1 2022 and 9 closed out, a net change of -4 holders.
  • The largest Biotech Acquisition Company Warrant buyer in Q1 2022 was HGC Investment Management, an estimated $212K added.
  • The largest Biotech Acquisition Company Warrant seller in Q1 2022 was Ramius Advisors, an estimated $299K sold.

Based on aggregated 13F filings for Q1 2022.